Iron and the liver: Update 2008

Journal of Hepatology

Volumn 48, Issue SUPPL. 1, 2008, Pages

  Deugnier, Yves ^a   Brissot, Pierre ^b   Loréal, Olivier ^b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Haemochromatosis; Hepatic iron overload; Iron metabolism

Indexed keywords

CERULOPLASMIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERROPORTIN; HEMOJUVELIN; HEPCIDIN; HFE PROTEIN; NIFEDIPINE; PROTON PUMP INHIBITOR; TRANSFERRIN; TRANSFERRIN RECEPTOR 2;

ALCOHOL CONSUMPTION; BLOOD DONOR; CHRONIC LIVER DISEASE; CREATININE BLOOD LEVEL; DIETARY INTAKE; DISEASE CLASSIFICATION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HELICOBACTER INFECTION; HEMOCHROMATOSIS; HEMOSIDEROSIS; HUMAN; INFLAMMATION; IRON ABSORPTION; IRON METABOLISM; IRON OVERLOAD; METABOLIC SYNDROME X; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THALASSEMIA; TREATMENT INDICATION;

EID: 40849097485     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.01.014     Document Type: Review

References (84)

1. Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A., Basava A., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13 (1996) 399-408
2. Krause A., Neitz S., Magert H.J., Schulz A., Forssmann W.G., Schulz-Knappe P., et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480 (2000) 147-150
3. Park C.H., Valore E.V., Waring A.J., and Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276 (2001) 7806-7810
4. Pigeon C., Ilyin G., Courselaud B., Leroyer P., Turlin B., Brissot P., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276 (2001) 7811-7819
5. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., and Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101 (2003) 2461-2463
6. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 18 (2007) 394-400
7. Loreal O., Haziza-Pigeon C., Troadec M.B., Detivaud L., Turlin B., Courselaud B., et al. Hepcidin in iron metabolism. Curr Protein Pept Sci 6 (2005) 279-291
8. Nicolas G., Bennoun M., Devaux I., Beaumont C., Grandchamp B., Kahn A., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 98 (2001) 8780-8785
9. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
10. Bekri S., Gual P., Anty R., Luciani N., Dahman M., Ramesh B., et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131 (2006) 788-796
11. Peyssonnaux C., Zinkernagel A.S., Datta V., Lauth X., Johnson R.S., and Nizet V. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 107 (2006) 3727-3732
12. Nicolas G., Chauvet C., Viatte L., Danan J.L., Bigard X., Devaux I., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110 (2002) 1037-1044
13. Anderson G.J., Darshan D., Wilkins S.J., and Frazer D.M. Regulation of systemic iron homeostasis: how the body responds to changes in iron demand. Biometals 20 (2007) 665-674
14. Babitt J.L., Huang F.W., Wrighting D.M., Xia Y., Sidis Y., Samad T.A., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38 (2006) 531-539
15. Wang R.H., Li C., Xu X., Zheng Y., Xiao C., Zerfas P., et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2 (2005) 399-409
16. Truksa J., Peng H., Lee P., and Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci USA 103 (2006) 10289-10293
17. Papanikolaou G., Samuels M.E., Ludwig E.H., MacDonald M.L., Franchini P.L., Dube M.P., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile haemochromatosis. Nat Genet 36 (2004) 77-82
18. Goswami T., and Andrews N.C. Hereditary haemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 281 (2006) 28494-28498
19. Calzolari A., Raggi C., Deaglio S., Sposi N.M., Stafsnes M., Fecchi K., et al. TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci 119 (2006) 4486-4498
20. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003) 1-20
21. Verga Falzacappa M.V., Vujic Spasic M., Kessler R., Stolte J., Hentze M.W., and Muckenthaler M.U. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109 (2007) 353-358
22. Courselaud B., Pigeon C., Inoue Y., Inoue J., Gonzalez F.J., Leroyer P., et al. C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem 277 (2002) 41163-41170
23. Lin L., Valore E.V., Nemeth E., Goodnough J.B., Gabayan V., and Ganz T. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 110 (2007) 2182-2189
24. Tanno T., Bhanu N.V., Oneal P.A., Goh S.H., Staker P., Lee Y.T., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13 (2007) 1096-1101
25. Pietrangelo A. Haemochromatosis: an endocrine liver disease. Hepatology 46 (2007) 1291-1301
26. Camaschella C., Roetto A., Cali A., De Gobbi M., Garozzo G., Carella M., et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 25 (2000) 14-15
27. Pietrangelo A. Non-HFE haemochromatosis. Hepatology 39 (2004) 21-29
28. Kono S., Suzuki H., Takahashi K., Takahashi Y., Shirakawa K., Murakawa Y., et al. Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia. Gastroenterology 131 (2006) 240-245
29. Miyajima H., Takahashi Y., and Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 16 (2003) 205-213
30. Beutler E., Gelbart T., Lee P., Trevino R., Fernandez M.A., and Fairbanks V.F. Molecular characterization of a case of atransferrinemia. Blood 96 (2000) 4071-4074
31. Beaumont C., Delaunay J., Hetet G., Grandchamp B., de Montalembert M., and Tchernia G. Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload. Blood 107 (2006) 4168-4170
32. Iolascon A., d'Apolito M., Servedio V., Cimmino F., Piga A., and Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood 107 (2006) 349-354
33. Mims M.P., Guan Y., Pospisilova D., Priwitzerova M., Indrak K., Ponka P., et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 105 (2005) 1337-1342
34. Deugnier Y., Loreal O., Carre F., Duvallet A., Zoulim F., Vinel J.P., et al. Increased body iron stores in elite road cyclists. Med Sci Sports Exerc 34 (2002) 876-880
35. Nemeth E., and Ganz T. Hepcidin and iron-loading anemias. Haematologica 91 (2006) 727-732
36. Deugnier Y., Turlin B., le Quilleuc D., Moirand R., Loreal O., Messner M., et al. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of haemochromatosis. Am J Surg Pathol 21 (1997) 669-675
37. Ludwig J., Hashimoto E., Porayko M.K., Moyer T.P., and Baldus W.P. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 112 (1997) 882-888
38. Detivaud L., Nemeth E., Boudjema K., Turlin B., Troadec M.B., Leroyer P., et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 106 (2005) 746-748
39. Gandon Y., Olivie D., Guyader D., Aube C., Oberti F., Sebille V., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 363 (2004) 357-362
40. Pietrangelo A. Haemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 124 (2003) 1509-1523
41. Harrison-Findik D.D. Role of alcohol in the regulation of iron metabolism. World J Gastroenterol 13 (2007) 4925-4930
42. Mendler M.H., Turlin B., Moirand R., Jouanolle A.M., Sapey T., Guyader D., et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 117 (1999) 1155-1163
43. Moirand R., Mortaji A.M., Loreal O., Paillard F., Brissot P., and Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 349 (1997) 95-97
44. Laine F., and Deugnier Y. Increased expression of hepcidin in obese patients: impact on phenotypic expression of haemochromatosis and pathophysiology of dysmetabolic iron overload syndrome. Gastroenterology 131 (2006) 2028
45. Adams P.C., Reboussin D.M., Barton J.C., McLaren C.E., Eckfeldt J.H., McLaren G.D., et al. Haemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352 (2005) 1769-1778
46. Beutler E., Felitti V.J., Koziol J.A., Ho N.J., and Gelbart T. Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002) 211-218
47. Deugnier Y., Jouanolle A.M., Chaperon J., Moirand R., Pithois C., Meyer J.F., et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol 118 (2002) 1170-1178
48. Olynyk J.K., Cullen D.J., Aquilia S., Rossi E., Summerville L., and Powell L.W. A population-based study of the clinical expression of the haemochromatosis gene. N Engl J Med 341 (1999) 718-724
49. Beutler E. Iron storage disease: facts, fiction and progress. Blood Cells Mol Dis 39 (2007) 140-147
50. Pietrangelo A. The penetrance of haemochromatosis: mice to the rescue. Gastroenterology 132 (2007) 805-808
51. van der A.D., Peeters P.H., Grobbee D.E., Roest M., Voorbij H.A., and van der Schouw Y.T. HFE genotypes and dietary heme iron: no evidence of strong gene-nutrient interaction on serum ferritin concentrations in middle-aged women. Nutr Metab Cardiovasc Dis 16 (2006) 60-68
52. Cade J.E., Moreton J.A., O'Hara B., Greenwood D.C., Moor J., Burley V.J., et al. Diet and genetic factors associated with iron status in middle-aged women. Am J Clin Nutr 82 (2005) 813-820
53. Kaltwasser J.P., Werner E., Schalk K., Hansen C., Gottschalk R., and Seidl C. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 43 (1998) 699-704
54. Bridle K., Cheung T.K., Murphy T., Walters M., Anderson G., Crawford D.G., et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 30 (2006) 106-112
55. Harrison-Findik D.D., Klein E., Crist C., Evans J., Timchenko N., and Gollan J. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 46 (2007) 1879-1885
56. Harrison-Findik D.D., Schafer D., Klein E., Timchenko N.A., Kulaksiz H., Clemens D., et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 281 (2006) 22974-22982
57. Barton J.C., Preston B.L., McDonnell S.M., and Rothenberg B.E. Severity of iron overload in haemochromatosis: effect of volunteer blood donation before diagnosis. Transfusion 41 (2001) 123-129
58. Laine F., Jouannolle A.M., Morcet J., Brigand A., Pouchard M., Lafraise B., et al. Phenotypic expression in detected C282Y homozygous women depends on body mass index. J Hepatol 43 (2005) 1055-1059
59. Beutler E., Waalen J., and Gelbart T. Chronic inflammation does not appear to modify the homozygous hereditary haemochromatosis phenotype. Blood Cells Mol Dis 35 (2005) 326-327
60. Hutchinson C., Geissler C.A., Powell J.J., and Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 56 (2007) 1291-1295
61. 2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat Med 13 (2007) 448-454
62. Beutler E., and Gelbart T. Helicobacter pylori infection and HFE haemochromatosis. Blood Cells Mol Dis 37 (2006) 188-191
63. Moirand R., Adams P.C., Bicheler V., Brissot P., and Deugnier Y. Clinical features of genetic haemochromatosis in women compared with men. Ann Intern Med 127 (1997) 105-110
64. Jacolot S., Le Gac G., Scotet V., Quere I., Mura C., and Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 103 (2004) 2835-2840
65. Merryweather-Clarke A.T., Cadet E., Bomford A., Capron D., Viprakasit V., Miller A., et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 12 (2003) 2241-2247
66. Le Gac G., Scotet V., Ka C., Gourlaouen I., Bryckaert L., Jacolot S., et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 13 (2004) 1913-1918
67. Milet J., Dehais V., Bourgain C., Jouanolle A.M., Mosser A., Perrin M., et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE haemochromatosis penetrance. Am J Hum Genet 81 (2007) 799-807
68. Fletcher L.M., Bridle K.R., and Crawford D.H. Effect of alcohol on iron storage diseases of the liver. Best Pract Res Clin Gastroenterol 17 (2003) 663-677
69. Loréal O., Deugnier Y., Moirand R., Lauvin L., Guyader D., Jouanolle H., et al. Liver fibrosis in genetic haemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol 16 (1992) 122-127
70. Powell E.E., Ali A., Clouston A.D., Dixon J.L., Lincoln D.J., Purdie D.M., et al. Steatosis is a cofactor in liver injury in haemochromatosis. Gastroenterology 129 (2005) 1937-1943
71. Valenti L., Conte D., Piperno A., Dongiovanni P., Fracanzani A.L., Fraquelli M., et al. The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J Med Genet 41 (2004) 946-950
72. Osterreicher C.H., Datz C., Stickel F., Hellerbrand C., Penz M., Hofer H., et al. TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary haemochromatosis. Cytokine 31 (2005) 142-148
73. Distante S., Berg J.P., Lande K., Haug E., and Bell H. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut 47 (2000) 575-579
74. Walsh A., Dixon J.L., Ramm G.A., Hewett D.G., Lincoln D.J., Anderson G.J., et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in haemochromatosis. Clin Gastroenterol Hepatol 4 (2006) 1403-1410
75. Pietrangelo A., Corradini E., Ferrara F., Vegetti A., De Jong G., Luca Abbati G., et al. Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease. Blood Cells Mol Dis 37 (2006) 192-196
76. Deugnier Y., and Turlin B. Pathology of hepatic iron overload. World J Gastroenterol 13 (2007) 4755-4760
77. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 32 (2004) 131-138
78. Guyader D., Jacquelinet C., Moirand R., Turlin B., Mendler M.H., Chaperon J., et al. Noninvasive prediction of fibrosis in C282Y homozygous haemochromatosis. Gastroenterology 115 (1998) 929-936
79. Falize L., Guillygomarc'h A., Perrin M., Laine F., Guyader D., Brissot P., et al. Reversibility of hepatic fibrosis in treated genetic haemochromatosis: a study of 36 cases. Hepatology 44 (2006) 472-477
80. Laine F., Bendavid C., Moirand R., Tessier S., Perrin M., Guillygomarc'h A., et al. Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology 39 (2004) 1639-1646
81. Loréal O., Turlin B., Pigeon C., Moisan A., Ropert M., Morice P., et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 36 (2000) 851-856
82. Miyajima H., Takahashi Y., Kamata T., Shimizu H., Sakai N., and Gitlin J.D. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 41 (1997) 404-407
83. Cappellini M.D., Cohen A., Piga A., Bejaoui M., Perrotta S., Agaoglu L., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3455-3462
84. Brissot P., and de Bels F. Current approaches to the management of haemochromatosis. Hematology (2006) 36-41